Weitere Artikel dieser Ausgabe durch Wischen aufrufen
The loss of skeletal mass – sarcopenia and cachexia – is considered to be a major contributor to morbidity and mortality in chronic heart failure (CHF). Unfortunately, sarcopenia is generally considered to be a geriatric syndrome, but not necessarily seen as a comorbidity in CHF, even though it has a wide range of adverse health outcomes. While there were 15,574 publication with the title word “heart failure” in PubMed in the 5‑year period from 1 June 2011 to 31 May 2016, only 22 or 71 publications were found with the search combination “sarcopenia” or “cachexia” (title word) and “heart failure” (all fields), respectively. This shows very clearly that loss of muscle quality and function due to heart failure is still an underappreciated problem in the medical field.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Cowie MR, Anker SD, Cleland JGF, Felker GM, Filippatos G, Jaarsma T, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. Esc Heart Fail. 2014;1:110–45. CrossRef
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;2016(18):891–975. CrossRef
Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1:4–25. CrossRef
Greene SJ, Fonarow GC, Solomon SD, Subacius H, Maggioni AP, Bohm M, et al. Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. Eur J Heart Fail. 2015;17:591–600. PubMedCrossRef
Harikrishnan S, Sanjay G, Anees T, Viswanathan S, Vijayaraghavan G, Bahuleyan CG, et al. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. Eur J Heart Fail. 2015;17:794–800. PubMedCrossRef
Chen LK, Lee WJ, Peng LN, Liu LK, Arai H, Akishita M. Recent advances in sarcopenia research in Asia: 2016 update from the asian working group for sarcopenia. J Am Med Dir Assoc. 2016;17:767:e1–7.
Hassanein M, Abdelhamid M, Ibrahim B, Elshazly A, Aboleineen MW, Sobhy H, et al. Clinical characteristics and management of hospitalized and ambulatory patients with heart failure-results from ESC heart failure long-term registry-Egyptian cohort. ESC Heart Fail. 2015;2:159–67. CrossRef
Steinbeck L, Ebner N, Valentova M, Bekfani T, Elsner S, Dahinden P, et al. Detection of muscle wasting in patients with chronic heart failure using C‑terminal agrin fragment: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur J Heart Fail. 2015;17:1283–93. PubMedCrossRef
Yamada S, Kamiya K, Kono Y. Frailty may be a risk marker for adverse outcome in patients with congestive heart failure. ESC Heart Fail. 2015;2:168–70. CrossRef
von Haehling S, Steinbeck L, Doehner W, Springer J, Anker SD. Muscle wasting in heart failure: an overview. Int J Biochem Cell Biol. 2013;45:2257–65. CrossRef
Doehner W, Turhan G, Leyva F, Rauchhaus M, Sandek A, Jankowska EA, et al. Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure. ESC Heart Fail. 2015;2:85–9. CrossRef
Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Barillaro C, et al. Association of anorexia with sarcopenia in a community-dwelling elderly population: results from the ilSIRENTE study. Eur J Nutr. 2013;52:1261–8. PubMed
Fragala MS, Jajtner AR, Beyer KS, Townsend JR, Emerson NS, Scanlon TC, et al. Biomarkers of muscle quality: N‑terminal propeptide of type III procollagen and C‑terminal agrin fragment responses to resistance exercise training in older adults. J Cachexia Sarcopenia Muscle. 2014;5:139–48. PubMedCrossRef
Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. Clin Nutr (edinburgh Scotland). 2014;33:737–48. CrossRef
Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544–58. PubMedCrossRef
von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 2014;5:261–3. CrossRef
Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet (london England). 1997;349:1050–3. CrossRef
Anker SD, Kosiborod M, Zannad F, Pina IL, McCullough PA, Filippatos G, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17:1050–6. PubMedPubMedCentralCrossRef
Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet (london England). 2016;387:2412–21. CrossRef
Olivotto I, Hellawell JL, Farzaneh-Far R, Blair C, Coppini R, Myers J, et al. Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial. Circ Heart Fail. 2016;9:e002764. PubMedCrossRef
Pellicori P, Clark AL. Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failure. Eur J Heart Fail. 2015;17:979–83. PubMedCrossRef
Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133:282–90. PubMed
Le HH, El-Khatib C, Mombled M, Guitarian F, Al-Gobari M, Fall M, et al. Impact of aldosterone antagonists on sudden cardiac death prevention in heart failure and post-myocardial infarction patients: a systematic review and meta-analysis of randomized controlled trials. PLOS ONE. 2016;11:e0145958. PubMedPubMedCentralCrossRef
Chen CY, Stevenson LW, Stewart GC, Bhatt DL, Desai M, Seeger JD, et al. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure. BMJ. 2015;351:h3529. PubMedPubMedCentralCrossRef
Kizilarslanoglu MC, Kuyumcu ME, Yesil Y, Halil M. Sarcopenia in critically ill patients. J Anesth. 2016;30:884–90. PubMed
Jolley SE, Bunnell A, Hough CL. Intensive care unit acquired weakness. Chest. 2016. doi: 10.1016/j.chest.2016.03.045.
Ebner N, Sliziuk V, Scherbakov N, Sandek A. Muscle wasting in ageing and chronic illness. ESC Heart Fail. 2015;2:58–68. CrossRef
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755–63. PubMed
Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr. 2010;29:154–9. PubMedCrossRef
Dam TT, Peters KW, Fragala M, Cawthon PM, Harris TB, McLean R, et al. An evidence-based comparison of operational criteria for the presence of sarcopenia. J Gerontol Ser A Biol Sci Med Sci. 2014;69:584–90. CrossRef
Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, Maggio M, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2015;16:740–7. PubMedCrossRef
Vitale G, Cesari M, Mari D. Aging of the endocrine system and its potential impact on sarcopenia. Eur J Intern Med. 2016. doi: 10.1016/j.ejim.2016.07.017.
Adams SC, Segal RJ, McKenzie DC, Vallerand JR, Morielli AR, Mackey JR, et al. Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. Breast Cancer Res Treat. 2016;158:497–507. PubMedCrossRef
Gielen S, Sandri M, Kozarez I, Kratzsch J, Teupser D, Thiery J, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation. 2012;125:2716–27. PubMedCrossRef
Trippel TD, Holzendorf V, Halle M, Gelbrich G, Nolte K, Duvinage A, et al. Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study. ESC Heart Fail. 2016; doi: 10.1002/ehf2.12109.
Jaarsma T, Klompstra L, Ben GT, Boyne J, Vellone E, Back M, et al. Increasing exercise capacity and quality of life of patients with heart failure through Wii gaming: the rationale, design and methodology of the HF-Wii study; a multicentre randomized controlled trial. Eur J Heart Fail. 2015;17:743–8. PubMedPubMedCentralCrossRef
Konishi M, Ishida J, Springer J, Anker SD, von Haehling S. Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact. J Cachexia Sarcopenia Muscle. 2016; doi: 10.1002/jcsm.12117.
McAloon CJ, O’Hare P, Osman F, Randeva HS. The interplay between heart failure, metabolism and body composition. Br J Hosp Med. 2016;77:362–4. CrossRef
Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol (Oxf). 2016;85:436–43. CrossRef
Stewart Coats AJ, Ho GF, Prabhash K, von Haehling S, Tilson J, Brown R, et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016;7:355–65. PubMedPubMedCentralCrossRef
- Publication trends in cachexia and sarcopenia in elderly heart failure patients
PD Dr. Jochen Springer
Stefan D. Anker
- Springer Vienna